Abstract
Thiopurines and anti–tumor necrosis factor (TNF) are increasingly used during the pregnancy of women with inflammatory bowel disease (IBD). These drugs do not increase the rate of malformations and serious infections in children who have been exposed in utero. Yet, recent large-scale studies have shown that thiopurines are associated with increased rates of stillbirths, preterm births, and large for gestational age infants, whereas combination of thiopurines and anti-TNF is associated with increased rates of serious infections during the first year of life.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
